Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of “Reduce” by Brokerages

Minerva Neurosciences, Inc (NASDAQ:NERV) has earned an average rating of “Reduce” from the four research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $10.50.

Several analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Wednesday, June 24th. Zacks Research lowered shares of Minerva Neurosciences from a “hold” rating to a “strong sell” rating in a report on Wednesday. Jefferies Financial Group upgraded shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating in a research report on Friday. Finally, Wall Street Zen raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th.

Minerva Neurosciences Stock Performance

Shares of NERV stock opened at $3.92 on Friday. The stock has a market capitalization of $187.18 million, a price-to-earnings ratio of -0.14 and a beta of -0.10. Minerva Neurosciences has a 12-month low of $1.79 and a 12-month high of $12.46. The stock’s 50-day moving average price is $4.46 and its 200-day moving average price is $5.43.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. As a group, research analysts predict that Minerva Neurosciences will post -0.5 EPS for the current fiscal year.

Minerva Neurosciences News Summary

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: HC Wainwright’s longer-term projections remain optimistic, calling for positive EPS of $0.64 in fiscal 2029 and $1.67 in fiscal 2030. This indicates the firm still sees potential for meaningful profitability if Minerva’s development programs and commercialization plans succeed.
• Neutral Sentiment: The analyst forecasts EPS of negative $0.15 for fiscal 2028, followed by a return to profitability in 2029. The estimates imply that investors may need to look several years ahead for earnings growth.
• Negative Sentiment: HC Wainwright cut its fiscal 2026 EPS estimate to negative $0.50 from negative $0.20 and reduced its Q3 2026 estimate to negative $0.14 from negative $0.01. The firm also expects Q4 2026 EPS of negative $0.09, compared with its previous estimate of negative $0.01.
• Negative Sentiment: Forecasts for fiscal 2027 were sharply lowered to negative $0.42 per share from positive $4.82. Quarterly 2027 estimates were also reset to approximately negative $0.11 per share, including Q2, Q3 and Q4, signaling substantially weaker near-term earnings expectations.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NERV. Bank of New York Mellon Corp purchased a new position in Minerva Neurosciences in the second quarter worth about $419,000. Seven Fleet Capital Management LP bought a new stake in Minerva Neurosciences during the first quarter worth approximately $6,855,000. DV Trading LLC purchased a new stake in Minerva Neurosciences during the first quarter valued at approximately $5,358,000. Bank of America Corp DE raised its position in Minerva Neurosciences by 78,272.5% during the first quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 39,919 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Minerva Neurosciences by 47,614.0% in the 1st quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock worth $25,873,000 after purchasing an additional 4,285,259 shares during the period. Institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.